Overview
Availability
- Associate Professor David Wyld is:
- Available for supervision
Works
Search Professor David Wyld’s works on UQ eSpace
2007
Journal Article
A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma
Kefford, Richard, Beith, Jane McNeil, Van Hazel, Guy Arthur, Millward, Michael, Trotter, James Marshall, Wyld, David Keith, Kusic, Rada, Shreeniwas, Revati, Morganti, Adele, Ballmer, Andrea, Segal, Eleonor, Nayler, Oliver and Clozel, Martine (2007). A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Investigational New Drugs, 25 (3), 247-252. doi: 10.1007/s10637-006-9014-7
2007
Journal Article
Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer
Friedlander, M, Buck, M, Wyld, D, Findlay, M, Fitzharris, B, De Souza, P, Davies, T, Kalimi, G, Allan, S, Perez, D and Harnett, P (2007). Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. International Journal of Gynecological Cancer, 17 (2), 350-358. doi: 10.1111/j.1525-1438.2007.00795.x
2006
Journal Article
Metastatic paraganglioma with extensive bone marrow involvement
Morris, Kirk L., Macfarlane, David, Wyld, David and Kennedy, Glen A. (2006). Metastatic paraganglioma with extensive bone marrow involvement. Asia-Pacific Journal of Clinical Oncology, 2 (4), 193-194. doi: 10.1111/j.1743-7563.2006.00068.x
2005
Conference Publication
Analysis of expression of Eph/Ephrin tyrosine kinases in advanced ovarian cancer.
Sabesan, SS, Wyld, D, Herath, N and Boyd, A (2005). Analysis of expression of Eph/Ephrin tyrosine kinases in advanced ovarian cancer.. 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando Fl, May 13-17, 2005. AMER SOC CLINICAL ONCOLOGY.
2005
Conference Publication
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage TV metastatic melanoma
Kefford, R, Beith, J, Van Hazel, GA, Millward, M, Trotter, J, Wyld, D, Kusic, R, Coward, J, Shreeniwas, R and Morganti, A (2005). A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage TV metastatic melanoma. ESMO Scientific and Educational Conference (ESEC), Budapest Hungary, Jun 02-05, 2005. OXFORD: OXFORD UNIV PRESS.
2004
Journal Article
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
Le Chevalier, T., Arriagada, R., Le Pechoux, C., Grunenwald, D., Dunant, A., Pignon, J. P., Tarayre, M., Abratt, R., Arriagada, R., Bergman, B., Gralla, R., Grunenwald, D., Le Chevalier, T., Orlowski, T., Papadakis, E., Pinel, M. I. Sathler, Araujo, C., Della Torre, H., de Solchaga, M. Masetto, Abdi, E., Blum, R., Ball, D., Basser, R., De Boer, R., Bishop, J., Brigham, B., Davis, S., Fox, D., Richardson, G. ... Wedel, H. (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New England Journal of Medicine, 350 (4), 351-360. doi: 10.1056/NEJMoa031644
2000
Journal Article
Conquering chemotherapy
Horwood, Keith and Wyld, David (2000). Conquering chemotherapy. Australian Prescriber, 23 (3).
2000
Journal Article
Conquering chemotherapy [3] (multiple letters)
Allison, R., Horwood, K. and Wyld, D. (2000). Conquering chemotherapy [3] (multiple letters). Australian Prescriber, 23 (3).
2000
Journal Article
Cisplatin-based therapy: A neurological and neuropsychological review
Troy, L., McFarland, K., Littman-Power, S., Kelly, B.J., Walpole, E.T., Wyld, D. and Thomson, D. (2000). Cisplatin-based therapy: A neurological and neuropsychological review. Psycho-Oncology, 9 (1), 29-39. doi: 10.1002/(SICI)1099-1611(200001/02)9:13.0.CO;2-Z
2000
Journal Article
Cisplatin-based therapy: A neurological and neurophysical review
Troy, L., McFarland, K. A., Littman-Powers, S., Kelly, B. J., Walpole, E. T., Wyld, D. and Thomson, D. (2000). Cisplatin-based therapy: A neurological and neurophysical review. Psychooncology, 9 (1), 29-39. doi: 10.1002/(SICI)1099-1611(200001/02)9:1
1999
Book Chapter
The impact of Cisplatin-based chemotherapy on everyday attention
Troy, L., Littmann-Power, S. C., Kelly, B. J., Thomson, D. and Wyld, D. (1999). The impact of Cisplatin-based chemotherapy on everyday attention. Brain Impairment and Rehabilitation: A National Perspective. (pp. 140-142) Brisbane: Aust. Academic Press.
1998
Journal Article
Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20
Wyld, DK, Selby, P, Perren, TJ, Jonas, SK, Allen-Mersh, TG, Wheeldon, J and Burchill, SA (1998). Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20. International Journal of Cancer, 79 (3), 288-293. doi: 10.1002/(SICI)1097-0215(19980619)79:33.3.CO;2-2
1998
Journal Article
Endocrine aspects of the clinical management of breast cancer - Current issues
Wyld, DK, Chester, JD and Perren, TJ (1998). Endocrine aspects of the clinical management of breast cancer - Current issues. Endocrine-Related Cancer, 5 (2), 97-110. doi: 10.1677/erc.0.0050097
1998
Book Chapter
Breast cancer
Wyld, D. (1998). Breast cancer. Key Topics in Oncology. (pp. 30-36) edited by G D Hall, P M Patel and A S Protheroe. Oxford, United Kingdom: Bios Scientific Publication.
Supervision
Availability
- Associate Professor David Wyld is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Completed supervision
-
2020
Master Philosophy
Predictors of dosimetry and outcome to peptide receptor radionuclide therapy in metastatic neuroendocrine tumour.
Principal Advisor
Other advisors: Associate Professor David Pattison
-
2021
Doctor Philosophy
Targeting receptor activator of NF-kB pathways in combination immunotherapy
Associate Advisor
Media
Enquiries
For media enquiries about Associate Professor David Wyld's areas of expertise, story ideas and help finding experts, contact our Media team: